No profile data available.
China Pharma Holdings, Inc. (CPHI) is a healthcare company in the antibacterial pharmaceuticals industry, based in Haikou, China, with about 215 full-time employees.
It reported revenue of $4.14 million for fiscal year 2025, down 8.5% from fiscal year 2024, and net income of -$3.19 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $983,536, down 13.4% from a year before. Its market capitalization was $37.45 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
China Pharma reported $4.14 million in revenue for fiscal year 2025, down 8.5% from $4.53 million in fiscal year 2024. In Q1 2026 revenue was $983,536.
$37.45 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include Armata Pharmaceuticals, Inc. (ARMP), PolyPid Ltd. (PYPD), Spero Therapeutics, Inc. (SPRO), Evaxion A/S (EVAX).